Full Text View
Tabular View
No Study Results Posted
Related Studies
Elsamitrucin (SPP 28090) in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
This study has been completed.
Study NCT00184080   Information provided by USC/Norris Comprehensive Cancer Center

First Received on September 13, 2005.   Last Updated on January 18, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Non-Hodgkin's Lymphoma
Additional conditions recognized in this trial
Lymphoma
Lymphoma, Non-Hodgkin
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
Elsamitrusin
Additional drug interventions recognized in this trial
Elsamicin A
More general drug interventions related to this trial
Antibiotics, Antineoplastic
Antineoplastic Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
USC/Norris Comprehensive Cancer Center
Spectrum Pharmaceuticals, Inc


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services